news
AstraZeneca’s Faslodex approved for new indication in the US
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
List view / Grid view
AstraZeneca
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
news
ProStrakan reaches deal for Moventig with AstraZeneca
1 March 2016 | By Victoria White
ProStrakan will make an upfront payment to AstraZeneca of $70 million to acquire the rights to Moventig in the EU, Iceland, Norway, Switzerland and Liechtenstein...
news
Tremelimumab mesothelioma trial fails to meet primary endpoint
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
news
Orphan drug designation recommended for acalabrutinib in three indications
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
news
EC approves AstraZeneca’s Brilique at a new 60mg dose
19 February 2016 | By Victoria White
After the first year, patients with a history of heart attack can now continue to be treated with Brilique at the lower dose of 60mg twice daily...
news
AstraZeneca’s Zurampic approved in the EU for patients with gout
19 February 2016 | By Victoria White
In combination with the current standard of care, Zurampic provides a dual mechanism of action to increase excretion and decrease production of uric acid...
news
BIO-Europe Spring® 2016 Event in Sweden this April will bring 2,000+ life science executives to Stockholm-Uppsala region
8 February 2016 | By EBD Group
The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016...
news
EC approves osimertinib in EGFR T790M mutation-positive NSCLC
3 February 2016 | By Victoria White
The European Commission (EC) has granted conditional marketing authorisation for AstraZeneca's Tagrisso (AZD9291, osimertinib) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
news
Allergan and AstraZeneca team up to develop ATM-AVI
29 January 2016 | By Victoria White
Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam...
news
FDA grants Breakthrough Therapy designation to Lynparza in mCRPC
28 January 2016 | By Victoria White
This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer...
news
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
news
Incyte and AstraZeneca announce new lung cancer trial collaboration
11 January 2016 | By Victoria White
Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…
news
FDA approves Zurampic for patients with gout
23 December 2015 | By Victoria White
The FDA has approved AstraZeneca’s Zurampic (lesinurad) in combination with xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout...
news
CHMP issues positive opinion for Tagrisso (osimertinib)
18 December 2015 | By Victoria White
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of AstraZeneca’s Tagrisso (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small…
news
CHMP issues positive opinion for AstraZeneca’s lesinurad
18 December 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending the marketing authorisation of lesinurad 200mg tablets for the adjunctive treatment of hyperuricaemia in adult gout patients...
